CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This research investigates how mutations in ribosomal proteins contribute to cancer, particularly in T-cell leukemia. By studying the RPL10 R98S mutation, the project aims to understand its role in cancer progression and potential therapeutic targets.
Cancer cells are defective in vital cell functions such as cell cycle control and response to growth signals.
We found that cancer cells acquire defects in yet another vital function: translation of mRNA into proteins.
We saw that 9.8% of children with T-cell leukemia (T-ALL) harbor acquired mutations in the ribosome, the cellular protein translation factory.
We found mutations in RPL10, RPL5 and RPL22, 3 proteins of the large 60S ribosomal subunit.
Strikingly, 6.5% of T-ALL patients had the sam…
KATHOLIEKE UNIVERSITEIT LEUVEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
VLAAMS INSTITUUT BIOTECHNOLOGIE FLANDERS INSTITUTE FOR BIOTECHNOLOGY
Belgium, ZWIJNAARDE - GENT
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
